COVID-19 continues to devastate communities across the globe affecting millions in the process. People who get infected with this disease often experience changes in their physical, mental, physiologic, and psychological domains. To date, it is still not clear how long these changes might last and the impact they might have on us in the long run.
Now, imagine a scenario where you have a perfectly healthy child. You do everything in your power to keep them safe. You provide everything they ask for like any other responsible parent out there. You generally feel happy about your life and your family because everything is slowly stabilizing in the wake of the COVID-19 pandemic. Then out of nowhere, you realize your child has these mild symptoms. Concerned as any parent would be, you take your child to a pediatrician for a check-up. Upon a thorough assessment, you get the news that your child has a serious and rare condition associated with COVID-19.
Not knowing about the future can be frightening, but what is even worse is not knowing whether your child will recover from a condition that even the CDC is still trying to understand. This has been the fate of thousands of parents whose young ones have developed multisystem inflammatory syndrome in children (MIS-C). The disease was first diagnosed in the United Kingdom around April 2020. At this time, parents reported their children experiencing symptoms similar to those observed in Kawasaki disease or toxic shock syndrome. After that, more cases emerged in different parts of the world.
What is MIS-C?
Multisystem inflammatory syndrome in children, also known as MIS-C, is a severe COVID-19 complication. It is sometimes referred to as pediatric multisystem inflammatory syndrome (PMIS). This disease generally causes inflammation on multiple body systems: the brain, lungs, heart, kidneys, skin, gastrointestinal tract, and eyes. The disease often develops about four weeks after a COVID-19 infection. In rare cases, MIS-C might occur after 8-10 weeks later.
According to the CDC, only about 1000 cases of MIS-C had been diagnosed in the United States as of October 4, 2020. However, the situation has worsened this year, with more children presenting with symptoms fitting the current definition for MIS-C.
As of November 1 this year, records show that MIS-C has affected 5,526 children, with 48 of them succumbing to the condition in the United States alone. According to the CDC, most of those who develop this condition are aged 5-11 years. Even so, MIS-C affects children of all ages, including infants. California and Georgia have the most reported cases of MIS-C in the United States, with Louisiana following closely. So far, only Vermont has no reported cases of this disease. The rest of the States have at least one documented case. The U.S territories of American Samoa, Virgin Islands, Palau, Guam, Northern Mariana Islands, Republic of the Marshall Islands, and Federated States of Micronesia have also not recorded any MIS-C cases.
Its exact cause remains a mystery more than a year after the first diagnosis. MIS-C is serious and life-threatening if not treated early, given that it affects several vital organs. Children diagnosed with this condition usually get better with appropriate treatment.
Risk Factors for MIS-C
MIS-C predominantly occurs in children who test positive for COVID-19. However, evidence now shows that being in contact with a person who is COVID-19 positive increases the risk of developing this disorder. In fact, reports show that two percent of MIS-C patients seemed perfectly healthy and had not been infected with COVID-19. However, they recently had contact with a COVID-19 infected person.
The male gender also is a risk factor for developing MIS-C. According to the data reported in the past 12 months, 60 percent of the patients have been male, with female children accounting for nearly 40 percent of the cases.
Race or ethnicity has also remained a defining factor, with non-Hispanic blacks, Latinos, and non-Hispanic whites accounting for most MIS-C cases. However, the condition affects non-Hispanic blacks and Latinos more consistent with the high COVID-19 prevalence in these populations.
Usually, children with MIS-C present with different symptoms. Over time, the CDC has isolated the most common signs and symptoms based on the recently established MIS-C surveillance system. These include:
- Fever (>38.0°C)
- Skin rash
- Bloodshot eyes
- Abdominal pain
Parents should watch for these symptoms in their children and seek immediate medical attention. The onset of more serious MIS-C symptoms might signal the need for emergency care. These signs generally include:
- Persistent chest pain
- Shortness of breath
- Hypersomnia or inability to stay awake
- Observable color changes on the lips, nail bed, or the child’s skin
This list only provides symptoms indicative of severe MIS-C disease. Even so, a child might present with other worrying signs. Parents should particularly stay vigilant if a child recently had a COVID-19 diagnosis. They should contact a pediatrician if they have concerns about the possibility of their child having MIS-C.
MIS-C is treatable, with full recovery expected in most children. Treatment starts with supportive care to help manage symptoms. A child with this condition often receives different drugs to assist in treating inflammation. The objective here is to avert permanent organ damage. In most cases, hospitalization is necessary, with severe cases requiring admission to the pediatric intensive care unit.
Children diagnosed with MIS-C should not engage in physical exercise for about 3-6 months. They usually require cardiology clearance before participating in sporting activities or physical activity. They need this long break to ensure their heart has fully recovered.